Key facts
- This page summarizes Noah L. Rosenberg's Form 4 filing for Travere Therapeutics, Inc. (TVTX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 17 Aug 2021, 19:39.
Noah L. Rosenberg - 13 Aug 2021 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- TVTX
- Reported as of
- 13 Aug 2021
- Net transaction value
- -$24,085
- SEC form
- 4
- Accepted by SEC
- 17 Aug 2021, 19:39:04 UTC
- Prior SEC filing
- 29 Jul 2021
- Next SEC filing
- 26 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Elizabeth E. Reed, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Noah L. Rosenberg filed Form 4 for Travere Therapeutics, Inc. (TVTX) on 17 Aug 2021.
Change
- Previous filing in this sequence was filed on 29 Jul 2021.
- Current net transaction value: -$24,085.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TVTX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +4,500
- Change %
- +10%
- Price
- $0.000000
- Shares after
- 49,021
- Date
- 13 Aug 2021
- Ownership
- Direct
- Footnotes
- F1
TVTX
transaction
Common Stock
Sale
- Transaction value
- $24,085
- Shares
- -1,407
- Change %
- -2.9%
- Price
- $17.12
- Shares after
- 47,614
- Date
- 17 Aug 2021
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 9,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On August 13, 2021, a portion of the PRSUs vested upon the Issuer's confirmation of the satisfaction of a performance criterion related to the interim data read-out from the PROTECT study.
Footnote F2
Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.